With its vaccine schedule, “Denmark has made a values choice to accept preventable hospitalizations and illnesses that other ...

It took 27 years, but Cytokinetics secured its first U.S. drug approval. On Friday, the Food and Drug Administration cleared ...

The Trump administration intends to make its most forceful attempt yet at restricting gender-affirming care for transgender ...

Two government officials told STAT that the White House has been involved in final decisions about the FDA's new priority ...

The award is in response to an “unsolicited proposal,” according to documents in the Federal Register. The University of ...

WASHINGTON — Brand drugmakers have agreed to donate bulk ingredients to a national stockpile as part of deals with the Trump ...

The New York Times once called John Lamattina, then Pfizer head of R&D, “Dr. Optimistic.” He’s not so optimistic now.

BioMarin's new CEO had promised Wall Street there would be deals, and with Amicus, it has one the market likes.

STAT is leading the way in covering the Trump administration’s changes in health care and medicine because our journalists ...

Nine drugmakers are set to unveil deals with the Trump administration to lower the prices of some of their drugs, marking the ...

President Trump weighs in on a debate between hard-liners on marijuana and those who want more research on its medical uses.

BioMarin is acquiring Amicus Therapeutics for $4.8 billion, merging two rare disease-focused biotechs founded around the turn ...